146 related articles for article (PubMed ID: 18193422)
41. Selective expansion and partial activation of human NK cells and NK receptor-positive T cells by IL-2 and IL-15.
Dunne J; Lynch S; O'Farrelly C; Todryk S; Hegarty JE; Feighery C; Doherty DG
J Immunol; 2001 Sep; 167(6):3129-38. PubMed ID: 11544298
[TBL] [Abstract][Full Text] [Related]
42. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
[TBL] [Abstract][Full Text] [Related]
43. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.
Duensing S; Hadam M; Körfer A; Schomburg A; Menzel T; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Dec; 4(4):170-3. PubMed ID: 1282326
[TBL] [Abstract][Full Text] [Related]
44. HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
Janssen RA; Buter J; Straatsma E; Heijn AA; Sleijfer DT; de Vries EG; Mulder NH; The TH; de Leij L
Cancer Immunol Immunother; 1993; 36(3):198-204. PubMed ID: 8439981
[TBL] [Abstract][Full Text] [Related]
45. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro.
Carson WE; Ross ME; Baiocchi RA; Marien MJ; Boiani N; Grabstein K; Caligiuri MA
J Clin Invest; 1995 Dec; 96(6):2578-82. PubMed ID: 8675621
[TBL] [Abstract][Full Text] [Related]
46. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.
Frederiksen KS; Lundsgaard D; Freeman JA; Hughes SD; Holm TL; Skrumsager BK; Petri A; Hansen LT; McArthur GA; Davis ID; Skak K
Cancer Immunol Immunother; 2008 Oct; 57(10):1439-49. PubMed ID: 18286285
[TBL] [Abstract][Full Text] [Related]
47. The effect of interleukin 2 and transforming growth factor-beta 2 (TGF-beta 2) on the proliferation and natural killer activity of decidual CD16- CD56bright natural killer cells.
Saito S; Morii T; Enomoto M; Sakakura S; Nishikawa K; Narita N; Ichijo M
Cell Immunol; 1993 Dec; 152(2):605-13. PubMed ID: 7504983
[TBL] [Abstract][Full Text] [Related]
48. Low-dose IL-2 induces CD56
McQuaid SL; Loughran ST; Power PA; Maguire P; Szczygiel A; Johnson PA
Clin Exp Immunol; 2020 Jun; 200(3):228-241. PubMed ID: 31989589
[TBL] [Abstract][Full Text] [Related]
49. Glycodelin-A stimulates the conversion of human peripheral blood CD16-CD56bright NK cell to a decidual NK cell-like phenotype.
Lee CL; Vijayan M; Wang X; Lam KKW; Koistinen H; Seppala M; Li RHW; Ng EHY; Yeung WSB; Chiu PCN
Hum Reprod; 2019 Apr; 34(4):689-701. PubMed ID: 30597092
[TBL] [Abstract][Full Text] [Related]
50. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
Pichert G; Jost LM; Fierz W; Stahel RA
Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
[TBL] [Abstract][Full Text] [Related]
51. In vivo regulation of transforming growth factor beta 1 transcription by immunotherapy: interleukin-2 impairs interferon-alpha-stimulated increase in steady-state mRNA levels of transforming growth factor beta 1.
Jahn B; Brieger J; Fenchel K; Mitrou PS; Bergmann L
Cancer Immunol Immunother; 1994 May; 38(5):304-10. PubMed ID: 8162612
[TBL] [Abstract][Full Text] [Related]
52. In-vitro activation of natural killer cells from regional lymph nodes of melanoma patients with interleukin-2 and interleukin-15.
Vuletić AM; Jovanić IP; Jurišić VB; Milovanović ZM; Nikolić SS; Tanić NT; Konjević GM
Melanoma Res; 2015 Feb; 25(1):22-34. PubMed ID: 25380182
[TBL] [Abstract][Full Text] [Related]
53. Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2.
Hellstrand K; Hermodsson S
Int Arch Allergy Appl Immunol; 1990; 92(4):379-89. PubMed ID: 2150668
[TBL] [Abstract][Full Text] [Related]
54. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding.
Voss SD; Robb RJ; Weil-Hillman G; Hank JA; Sugamura K; Tsudo M; Sondel PM
J Exp Med; 1990 Oct; 172(4):1101-14. PubMed ID: 1698909
[TBL] [Abstract][Full Text] [Related]
55. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
56. Low-dose IL-2 treatment: activation of discrete T- and NK-cell sub-populations in vivo.
Farace F; Angevin E; Dietrich PY; Leboullaire C; Vanderplancke J; Escudier B; Triebel F
Int J Cancer; 1995 Sep; 62(5):523-8. PubMed ID: 7665221
[TBL] [Abstract][Full Text] [Related]
57. Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors.
Federici C; Shahaj E; Cecchetti S; Camerini S; Casella M; Iessi E; Camisaschi C; Paolino G; Calvieri S; Ferro S; Cova A; Squarcina P; Bertuccini L; Iosi F; Huber V; Lugini L
Front Immunol; 2020; 11():262. PubMed ID: 32231660
[TBL] [Abstract][Full Text] [Related]
58. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
[TBL] [Abstract][Full Text] [Related]
59. Regulation of development of CD56 bright CD11c + NK-like cells with helper function by IL-18.
Li W; Okuda A; Yamamoto H; Yamanishi K; Terada N; Yamanishi H; Tanaka Y; Okamura H
PLoS One; 2013; 8(12):e82586. PubMed ID: 24376549
[TBL] [Abstract][Full Text] [Related]
60. Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2.
Seidel MG; Freissmuth M; Pehamberger H; Micksche M
Naunyn Schmiedebergs Arch Pharmacol; 1998 Sep; 358(3):382-9. PubMed ID: 9774227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
